dulaglutide vs Semaglutide (Rybelsus)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

dulaglutide · Trulicity

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01394952 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).

Next expected readout: April 2027 · NCT07537088 (registry estimate)

Reported efficacy

Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) (met)

Result source: NCT03495102

Semaglutide (Rybelsus)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT06050577 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdulaglutideSemaglutide (Rybelsus)
HbA1c, change-2.0% vs -1.1%−0.9 vs placebo1.5 mg · wk 28 · n 133NCT04591626
25 other results
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 132 · Phase 3 · primary NCT02597049
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 130 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 134 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 131 · Phase 3 · primary NCT02597049
  • -1.4% vs -0.7% wk 28 · n 150 · Phase 3 · primary NCT02152371
  • -1.4% vs -0.1% wk 24 · n 215 · Phase 3 · primary NCT01769378
  • -1.2% vs -1.1% 1.5 mg · wk 26 · n 138 · Phase 3 · primary NCT01621178
  • -1.7% vs -1.2% 1.5 mg · wk 26 · n 253 · Phase 3 · primary NCT01648582
  • -1.5% vs -0.9% 1.5 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -1.4% 1.5 mg weekly · wk 26 · n 279 · Phase 3 · primary NCT01624259
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.3% vs -1.2% 0.75 mg · wk 26 · n 252 · Phase 3 · primary NCT01648582
  • -1.2% vs -0.9% 0.75 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -0.9% wk 26 · n 178 · Phase 3 · primary NCT01584232
  • -1% vs 0.5% 1.5 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.5% vs 0.5% 0.75 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.9% vs -1.7% 1.5 mg · wk 156 · n 6579 · Phase 3 · secondary NCT04255433
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.5% vs -0.9% 1.5 mg · wk 52 · n 253 · Phase 3 · secondary NCT01648582
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.0% vs -0.9% 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.4% vs -0.4% 4.5 mg · wk 18 · n 66 · Phase 2 · primary NCT02973100
  • -1.3% vs -0.4% 3.0 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.2% vs -0.4% 1.5 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.4% vs 0.1% wk 16 · n 120 · Phase 4 · primary NCT02750410
-1.6% vs -0.2%−1.4 vs placebo14 mg · wk 26 · n 116NCT04109547
34 other results
  • -1.5% vs -0.2% 7 mg · wk 26 · n 117 · Phase 3 · primary NCT04109547
  • -1.1% vs -0.2% 3 mg · wk 26 · n 114 · Phase 3 · primary NCT04109547
  • -0.7% vs -0.1% wk 104 · n 4076 · Phase 3 · secondary NCT03914326
  • -1% vs -0.3% n 1489 · Phase 3 · secondary NCT02692716
  • -1.2% vs -0.1% 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -1.2% vs -0.2% 14 mg · wk 52 · n 168 · Phase 3 · secondary NCT03021187
  • -0.9% vs -0.2% 7 mg · wk 52 · n 169 · Phase 3 · secondary NCT03021187
  • -0.6% vs -0.2% 3 mg · wk 52 · n 173 · Phase 3 · secondary NCT03021187
  • -1.5% vs 0.1% 14 mg · wk 52 · n 41 · Phase 3 · secondary NCT03018028
  • -1.4% vs 0.1% 7 mg · wk 52 · n 43 · Phase 3 · secondary NCT03018028
  • -1% vs 0.1% 3 mg · wk 52 · n 38 · Phase 3 · secondary NCT03018028
  • -1.3% vs -0.9% 14 mg · wk 52 · n 384 · Phase 3 · secondary NCT02863328
  • -1.2% vs -0.7% 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.1% vs -0.7% 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1% vs -0.7% 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.9% vs -0.7% 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8% vs -1.4% 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2% vs -1.6% 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.4% vs -1.4% 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.7% vs -1.6% 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.8% vs -1.4% 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.1% vs -1.6% 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -1.3% vs -0.8% wk 52 · n 230 · Phase 3 · secondary NCT02849080
  • -0.2% vs 0% wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.0% vs -0.4% 40 mg · wk 26 · n 46 · Phase 2 · primary NCT01923181
  • -1.8% vs -0.4% 40 mg · wk 26 · n 52 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 40 mg · wk 26 · n 44 · Phase 2 · primary NCT01923181
  • -1.7% vs -0.4% 20 mg · wk 26 · n 48 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 10 mg · wk 26 · n 57 · Phase 2 · primary NCT01923181
  • -1.2% vs -0.4% 5 mg · wk 26 · n 58 · Phase 2 · primary NCT01923181
  • -0.9% vs -0.4% 2.5 mg · wk 26 · n 56 · Phase 2 · primary NCT01923181
  • -1.2% vs -1.0% wk 52 · n 326 · Phase 4 · primary NCT05035082
Body weight, change (kg)-0.8 vs 0.4−1.2 vs placebo1.5 mg · wk 28 · n 133NCT04591626
18 other results
  • -1.9 vs 0.5 wk 28 · n 150 · Phase 3 · secondary NCT02152371
  • -0.9 vs -0.2 wk 24 · n 212 · Phase 3 · secondary NCT01769378
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.1 vs 1.4 1.5 mg · wk 52 · n 258 · Phase 3 · secondary NCT01648582
  • -2.8 vs 1.1 1.5 mg · wk 26 · n 140 · Phase 3 · secondary NCT01621178
  • -1.5 vs 1.0 1.5 mg · wk 26 · n 258 · Phase 3 · secondary NCT01648582
  • -1.5 vs 0.9 1.5 mg · wk 26 · n 222 · Phase 3 · secondary NCT01644500
  • -2.9 vs -3.6 1.5 mg weekly · wk 26 · n 299 · Phase 3 · secondary NCT01624259
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -0.8 vs 1.4 0.75 mg · wk 52 · n 257 · Phase 3 · secondary NCT01648582
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -0.9 vs 1.0 0.75 mg · wk 26 · n 257 · Phase 3 · secondary NCT01648582
  • -0.8 vs 0.9 0.75 mg · wk 26 · n 224 · Phase 3 · secondary NCT01644500
  • -0.5 vs 0.9 wk 26 · n 180 · Phase 3 · secondary NCT01584232
  • -4.1 vs -1.6 4.5 mg · wk 18 · n 67 · Phase 2 · secondary NCT02973100
  • -3.9 vs -1.6 3.0 mg · wk 18 · n 74 · Phase 2 · secondary NCT02973100
  • -2.8 vs -1.6 1.5 mg · wk 18 · n 72 · Phase 2 · secondary NCT02973100
  • -0.2 vs -0.3 wk 16 · n 120 · Phase 4 · secondary NCT02750410
-4.2 vs -1.3−2.9 vs placebowk 104 · n 4251NCT03914326
39 other results
  • -4.2 vs -0.8 n 1510 · Phase 3 · secondary NCT02692716
  • -4.4 vs -1 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -3.8 vs 0.5 14 mg · wk 52 · n 170 · Phase 3 · secondary NCT03021187
  • -3.1 vs -1.1 14 mg · wk 26 · n 116 · Phase 3 · secondary NCT04109547
  • -2.2 vs 0.5 7 mg · wk 52 · n 171 · Phase 3 · secondary NCT03021187
  • -2.9 vs -1 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -0.8 vs -1 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -2.2 vs -1.1 7 mg · wk 26 · n 119 · Phase 3 · secondary NCT04109547
  • -0.9 vs 0.5 3 mg · wk 52 · n 174 · Phase 3 · secondary NCT03021187
  • -2.4 vs -1.1 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.2 vs -1.1 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • 0 vs -1 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs -1.1 3 mg · wk 26 · n 115 · Phase 3 · secondary NCT04109547
  • -0.4 vs -1.1 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -4 vs -3.7 14 mg · wk 52 · n 386 · Phase 3 · secondary NCT02863328
  • -3.5 vs -0.7 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -3.2 vs -1 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -3.8 vs -0.5 14 mg · wk 26 · n 300 · Phase 3 · secondary NCT04017832
  • -2.5 vs -0.7 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.8 vs -1 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.9 vs -0.5 7 mg · wk 26 · n 319 · Phase 3 · secondary NCT04017832
  • -1.6 vs -0.7 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8 vs -1 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.7 vs 1 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.2 vs 0.3 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -0.9 vs 1 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1 vs 0.3 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • 0 vs 1 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.4 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -0.1 vs 0.3 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -2.6 vs -0.9 wk 104 · n 93 · Phase 3 · secondary NCT02849080
  • -6.9 vs -1.2 40 mg · wk 26 · n 46 · Phase 2 · secondary NCT01923181
  • -5.9 vs -1.2 40 mg · wk 26 · n 51 · Phase 2 · secondary NCT01923181
  • -8.3 vs -1.2 40 mg · wk 26 · n 44 · Phase 2 · secondary NCT01923181
  • -5.8 vs -1.2 20 mg · wk 26 · n 47 · Phase 2 · secondary NCT01923181
  • -4.9 vs -1.2 10 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.9 vs -1.2 5 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.0 vs -1.2 2.5 mg · wk 26 · n 56 · Phase 2 · secondary NCT01923181
  • -3.9 vs -3.5 wk 52 · n 290 · Phase 4 · secondary NCT05035082
HbA1c below 7%75.9% vs 33.8%+42.1 vs placebo1.5 mg · wk 28 · n 133NCT04591626
8 other results
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 68.2% vs 20% 4.5 mg · wk 18 · n 66 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 3.0 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 1.5 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 0% vs 47.4% wk 16 · n 116 · Phase 4 · secondary NCT02750410
—Not posted · NCT07271251
Fasting plasma glucose, change-2.2 vs -2.4vs Insulin Glargine1.5 mg · wk 52 · n 253NCT01648582
3 other results
  • -2.4 vs -2.6 1.5 mg · wk 26 · n 253 · Phase 3 · secondary NCT01648582
  • -1.5 vs -2.4 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.7 vs -2.6 0.75 mg · wk 26 · n 252 · Phase 3 · secondary NCT01648582
-1.9 vs -0.7−1.2 vs placebo14 mg · wk 52 · n 285NCT02863419
39 other results
  • -1.6 vs -0.1 14 mg · wk 52 · n 181 · Phase 3 · secondary NCT03021187
  • -1.9 vs -0.2 14 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -2.0 vs -0.3 14 mg · wk 26 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.3 14 mg · wk 26 · n 151 · Phase 3 · secondary NCT02827708
  • -1.4 vs 0.5 14 mg · wk 26 · n 181 · Phase 3 · secondary NCT03021187
  • -1.1 vs -0.1 7 mg · wk 52 · n 182 · Phase 3 · secondary NCT03021187
  • -1.5 vs -0.2 7 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -1.1 vs 0.5 7 mg · wk 26 · n 182 · Phase 3 · secondary NCT03021187
  • -0.8 vs -0.1 3 mg · wk 52 · n 184 · Phase 3 · secondary NCT03021187
  • -0.9 vs -0.2 3 mg · wk 26 · n 166 · Phase 3 · secondary NCT02906930
  • -0.5 vs 0.5 3 mg · wk 26 · n 184 · Phase 3 · secondary NCT03021187
  • -2.3 vs 0.3 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.4 vs -0.4 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.6 vs 0.3 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs 0.3 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -2.0 vs -2.1 14 mg · wk 52 · n 411 · Phase 3 · secondary NCT02863328
  • -1.8 vs -1.0 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 26 · n 411 · Phase 3 · secondary NCT02863328
  • -1.7 vs -0.9 14 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -1.6 vs -0.9 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2 vs -0.5 14 mg · wk 26 · n 294 · Phase 3 · secondary NCT04017832
  • -1.3 vs -1.0 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.2 vs -0.9 7 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -1.1 vs -0.9 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.7 vs -2.2 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.8 vs -0.5 7 mg · wk 26 · n 317 · Phase 3 · secondary NCT04017832
  • -1.0 vs -1.0 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.8 vs -0.9 3 mg · wk 26 · n 466 · Phase 3 · secondary NCT02607865
  • -1.1 vs -0.9 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -2.2 vs -1.8 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.0 vs -1.8 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -2.3 vs -2.2 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.9 vs -1.8 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.0 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.2 vs -2.2 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -2.4 vs -1.4 wk 52 · n 229 · Phase 3 · secondary NCT02849080
  • -0.3 vs 0.0 wk 104 · n 92 · Phase 3 · secondary NCT02849080
3-point MACE (% with event)12% vs 13.4%−1.4 vs placebon 4949NCT01394952
1 other result
  • 13.1% vs 12.2% 1.5 mg · wk 259 · n 6579 · Phase 3 · primary NCT04255433
12% vs 13.8%−1.8 vs placebowk 265 · n 4825NCT03914326
1 other result

HbA1c, change

dulaglutide
-2.0% vs -1.1%−0.9 vs placebo1.5 mg · wk 28 · n 133NCT04591626
25 other results
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 132 · Phase 3 · primary NCT02597049
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 130 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 134 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 131 · Phase 3 · primary NCT02597049
  • -1.4% vs -0.7% wk 28 · n 150 · Phase 3 · primary NCT02152371
  • -1.4% vs -0.1% wk 24 · n 215 · Phase 3 · primary NCT01769378
  • -1.2% vs -1.1% 1.5 mg · wk 26 · n 138 · Phase 3 · primary NCT01621178
  • -1.7% vs -1.2% 1.5 mg · wk 26 · n 253 · Phase 3 · primary NCT01648582
  • -1.5% vs -0.9% 1.5 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -1.4% 1.5 mg weekly · wk 26 · n 279 · Phase 3 · primary NCT01624259
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.3% vs -1.2% 0.75 mg · wk 26 · n 252 · Phase 3 · primary NCT01648582
  • -1.2% vs -0.9% 0.75 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -0.9% wk 26 · n 178 · Phase 3 · primary NCT01584232
  • -1% vs 0.5% 1.5 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.5% vs 0.5% 0.75 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.9% vs -1.7% 1.5 mg · wk 156 · n 6579 · Phase 3 · secondary NCT04255433
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.5% vs -0.9% 1.5 mg · wk 52 · n 253 · Phase 3 · secondary NCT01648582
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.0% vs -0.9% 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.4% vs -0.4% 4.5 mg · wk 18 · n 66 · Phase 2 · primary NCT02973100
  • -1.3% vs -0.4% 3.0 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.2% vs -0.4% 1.5 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.4% vs 0.1% wk 16 · n 120 · Phase 4 · primary NCT02750410
Semaglutide (Rybelsus)
-1.6% vs -0.2%−1.4 vs placebo14 mg · wk 26 · n 116NCT04109547
34 other results
  • -1.5% vs -0.2% 7 mg · wk 26 · n 117 · Phase 3 · primary NCT04109547
  • -1.1% vs -0.2% 3 mg · wk 26 · n 114 · Phase 3 · primary NCT04109547
  • -0.7% vs -0.1% wk 104 · n 4076 · Phase 3 · secondary NCT03914326
  • -1% vs -0.3% n 1489 · Phase 3 · secondary NCT02692716
  • -1.2% vs -0.1% 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -1.2% vs -0.2% 14 mg · wk 52 · n 168 · Phase 3 · secondary NCT03021187
  • -0.9% vs -0.2% 7 mg · wk 52 · n 169 · Phase 3 · secondary NCT03021187
  • -0.6% vs -0.2% 3 mg · wk 52 · n 173 · Phase 3 · secondary NCT03021187
  • -1.5% vs 0.1% 14 mg · wk 52 · n 41 · Phase 3 · secondary NCT03018028
  • -1.4% vs 0.1% 7 mg · wk 52 · n 43 · Phase 3 · secondary NCT03018028
  • -1% vs 0.1% 3 mg · wk 52 · n 38 · Phase 3 · secondary NCT03018028
  • -1.3% vs -0.9% 14 mg · wk 52 · n 384 · Phase 3 · secondary NCT02863328
  • -1.2% vs -0.7% 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.1% vs -0.7% 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1% vs -0.7% 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.9% vs -0.7% 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8% vs -1.4% 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2% vs -1.6% 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.4% vs -1.4% 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.7% vs -1.6% 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.8% vs -1.4% 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.1% vs -1.6% 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -1.3% vs -0.8% wk 52 · n 230 · Phase 3 · secondary NCT02849080
  • -0.2% vs 0% wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.0% vs -0.4% 40 mg · wk 26 · n 46 · Phase 2 · primary NCT01923181
  • -1.8% vs -0.4% 40 mg · wk 26 · n 52 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 40 mg · wk 26 · n 44 · Phase 2 · primary NCT01923181
  • -1.7% vs -0.4% 20 mg · wk 26 · n 48 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 10 mg · wk 26 · n 57 · Phase 2 · primary NCT01923181
  • -1.2% vs -0.4% 5 mg · wk 26 · n 58 · Phase 2 · primary NCT01923181
  • -0.9% vs -0.4% 2.5 mg · wk 26 · n 56 · Phase 2 · primary NCT01923181
  • -1.2% vs -1.0% wk 52 · n 326 · Phase 4 · primary NCT05035082

Body weight, change (kg)

dulaglutide
-0.8 vs 0.4−1.2 vs placebo1.5 mg · wk 28 · n 133NCT04591626
18 other results
  • -1.9 vs 0.5 wk 28 · n 150 · Phase 3 · secondary NCT02152371
  • -0.9 vs -0.2 wk 24 · n 212 · Phase 3 · secondary NCT01769378
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.1 vs 1.4 1.5 mg · wk 52 · n 258 · Phase 3 · secondary NCT01648582
  • -2.8 vs 1.1 1.5 mg · wk 26 · n 140 · Phase 3 · secondary NCT01621178
  • -1.5 vs 1.0 1.5 mg · wk 26 · n 258 · Phase 3 · secondary NCT01648582
  • -1.5 vs 0.9 1.5 mg · wk 26 · n 222 · Phase 3 · secondary NCT01644500
  • -2.9 vs -3.6 1.5 mg weekly · wk 26 · n 299 · Phase 3 · secondary NCT01624259
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -0.8 vs 1.4 0.75 mg · wk 52 · n 257 · Phase 3 · secondary NCT01648582
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -0.9 vs 1.0 0.75 mg · wk 26 · n 257 · Phase 3 · secondary NCT01648582
  • -0.8 vs 0.9 0.75 mg · wk 26 · n 224 · Phase 3 · secondary NCT01644500
  • -0.5 vs 0.9 wk 26 · n 180 · Phase 3 · secondary NCT01584232
  • -4.1 vs -1.6 4.5 mg · wk 18 · n 67 · Phase 2 · secondary NCT02973100
  • -3.9 vs -1.6 3.0 mg · wk 18 · n 74 · Phase 2 · secondary NCT02973100
  • -2.8 vs -1.6 1.5 mg · wk 18 · n 72 · Phase 2 · secondary NCT02973100
  • -0.2 vs -0.3 wk 16 · n 120 · Phase 4 · secondary NCT02750410
Semaglutide (Rybelsus)
-4.2 vs -1.3−2.9 vs placebowk 104 · n 4251NCT03914326
39 other results
  • -4.2 vs -0.8 n 1510 · Phase 3 · secondary NCT02692716
  • -4.4 vs -1 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -3.8 vs 0.5 14 mg · wk 52 · n 170 · Phase 3 · secondary NCT03021187
  • -3.1 vs -1.1 14 mg · wk 26 · n 116 · Phase 3 · secondary NCT04109547
  • -2.2 vs 0.5 7 mg · wk 52 · n 171 · Phase 3 · secondary NCT03021187
  • -2.9 vs -1 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -0.8 vs -1 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -2.2 vs -1.1 7 mg · wk 26 · n 119 · Phase 3 · secondary NCT04109547
  • -0.9 vs 0.5 3 mg · wk 52 · n 174 · Phase 3 · secondary NCT03021187
  • -2.4 vs -1.1 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.2 vs -1.1 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • 0 vs -1 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs -1.1 3 mg · wk 26 · n 115 · Phase 3 · secondary NCT04109547
  • -0.4 vs -1.1 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -4 vs -3.7 14 mg · wk 52 · n 386 · Phase 3 · secondary NCT02863328
  • -3.5 vs -0.7 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -3.2 vs -1 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -3.8 vs -0.5 14 mg · wk 26 · n 300 · Phase 3 · secondary NCT04017832
  • -2.5 vs -0.7 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.8 vs -1 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.9 vs -0.5 7 mg · wk 26 · n 319 · Phase 3 · secondary NCT04017832
  • -1.6 vs -0.7 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8 vs -1 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.7 vs 1 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.2 vs 0.3 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -0.9 vs 1 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1 vs 0.3 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • 0 vs 1 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.4 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -0.1 vs 0.3 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -2.6 vs -0.9 wk 104 · n 93 · Phase 3 · secondary NCT02849080
  • -6.9 vs -1.2 40 mg · wk 26 · n 46 · Phase 2 · secondary NCT01923181
  • -5.9 vs -1.2 40 mg · wk 26 · n 51 · Phase 2 · secondary NCT01923181
  • -8.3 vs -1.2 40 mg · wk 26 · n 44 · Phase 2 · secondary NCT01923181
  • -5.8 vs -1.2 20 mg · wk 26 · n 47 · Phase 2 · secondary NCT01923181
  • -4.9 vs -1.2 10 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.9 vs -1.2 5 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.0 vs -1.2 2.5 mg · wk 26 · n 56 · Phase 2 · secondary NCT01923181
  • -3.9 vs -3.5 wk 52 · n 290 · Phase 4 · secondary NCT05035082

HbA1c below 7%

dulaglutide
75.9% vs 33.8%+42.1 vs placebo1.5 mg · wk 28 · n 133NCT04591626
8 other results
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 68.2% vs 20% 4.5 mg · wk 18 · n 66 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 3.0 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 1.5 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 0% vs 47.4% wk 16 · n 116 · Phase 4 · secondary NCT02750410
Semaglutide (Rybelsus)
—Not posted · NCT07271251

Fasting plasma glucose, change

dulaglutide
-2.2 vs -2.4vs Insulin Glargine1.5 mg · wk 52 · n 253NCT01648582
3 other results
  • -2.4 vs -2.6 1.5 mg · wk 26 · n 253 · Phase 3 · secondary NCT01648582
  • -1.5 vs -2.4 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.7 vs -2.6 0.75 mg · wk 26 · n 252 · Phase 3 · secondary NCT01648582
Semaglutide (Rybelsus)
-1.9 vs -0.7−1.2 vs placebo14 mg · wk 52 · n 285NCT02863419
39 other results
  • -1.6 vs -0.1 14 mg · wk 52 · n 181 · Phase 3 · secondary NCT03021187
  • -1.9 vs -0.2 14 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -2.0 vs -0.3 14 mg · wk 26 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.3 14 mg · wk 26 · n 151 · Phase 3 · secondary NCT02827708
  • -1.4 vs 0.5 14 mg · wk 26 · n 181 · Phase 3 · secondary NCT03021187
  • -1.1 vs -0.1 7 mg · wk 52 · n 182 · Phase 3 · secondary NCT03021187
  • -1.5 vs -0.2 7 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -1.1 vs 0.5 7 mg · wk 26 · n 182 · Phase 3 · secondary NCT03021187
  • -0.8 vs -0.1 3 mg · wk 52 · n 184 · Phase 3 · secondary NCT03021187
  • -0.9 vs -0.2 3 mg · wk 26 · n 166 · Phase 3 · secondary NCT02906930
  • -0.5 vs 0.5 3 mg · wk 26 · n 184 · Phase 3 · secondary NCT03021187
  • -2.3 vs 0.3 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.4 vs -0.4 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.6 vs 0.3 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs 0.3 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -2.0 vs -2.1 14 mg · wk 52 · n 411 · Phase 3 · secondary NCT02863328
  • -1.8 vs -1.0 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 26 · n 411 · Phase 3 · secondary NCT02863328
  • -1.7 vs -0.9 14 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -1.6 vs -0.9 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2 vs -0.5 14 mg · wk 26 · n 294 · Phase 3 · secondary NCT04017832
  • -1.3 vs -1.0 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.2 vs -0.9 7 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -1.1 vs -0.9 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.7 vs -2.2 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.8 vs -0.5 7 mg · wk 26 · n 317 · Phase 3 · secondary NCT04017832
  • -1.0 vs -1.0 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.8 vs -0.9 3 mg · wk 26 · n 466 · Phase 3 · secondary NCT02607865
  • -1.1 vs -0.9 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -2.2 vs -1.8 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.0 vs -1.8 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -2.3 vs -2.2 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.9 vs -1.8 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.0 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.2 vs -2.2 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -2.4 vs -1.4 wk 52 · n 229 · Phase 3 · secondary NCT02849080
  • -0.3 vs 0.0 wk 104 · n 92 · Phase 3 · secondary NCT02849080

3-point MACE (% with event)

dulaglutide
12% vs 13.4%−1.4 vs placebon 4949NCT01394952
1 other result
  • 13.1% vs 12.2% 1.5 mg · wk 259 · n 6579 · Phase 3 · primary NCT04255433
Semaglutide (Rybelsus)
12% vs 13.8%−1.8 vs placebowk 265 · n 4825NCT03914326
1 other result
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. dulaglutide: 14 of 14 rows · Semaglutide (Rybelsus): 13 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdulaglutide
Rows use multiple source trials
Semaglutide (Rybelsus)
Rows use multiple source trials
BMI
absolute change · kg
-0.4 vs 0.52 Insulin Glargine kg @ 52wk1.5 mga,b,c
NCT01648582 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.27 vs 0.52 Insulin Glargine kg @ 52wk0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
-1.5 vs -1.4 Empagliflozin 25 mg kg @ 52wk14 mgb,c
NCT02863328 · Phase 3
14 other source trials
-1.2 vs -0.3 Sitagliptin kg @ 52wk14 mg
NCT02607865 · Phase 3
-0.6 vs -0.3 Sitagliptin kg @ 52wk3 mg
NCT02607865 · Phase 3
-0.9 vs -0.3 Sitagliptin kg @ 52wk7 mg
NCT02607865 · Phase 3
-1.6 vs -0.4 placebo kg @ 52wk14 mg
NCT02863419 · Phase 3
-1.4 vs 0.2 placebo kg @ 52wk14 mg
NCT03021187 · Phase 3
-0.3 vs 0.2 placebo kg @ 52wk3 mg
NCT03021187 · Phase 3
-0.8 vs 0.2 placebo kg @ 52wk7 mg
NCT03021187 · Phase 3
-1 vs -0.3 Sitagliptin kg @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
-1.1 vs -0.4 placebo kg @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0 vs -0.4 placebo kg @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.4 placebo kg @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.6 vs 0.3 Dulaglutide kg @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0 vs 0.3 Dulaglutide kg @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.3 vs 0.3 Dulaglutide kg @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Coronary Revascularization
event count · % of participants
9.4% (n=6579) vs 8% (n=6586) Tirzepatide @ 259wk*1.5 mgb,c,d
NCT04255433 · Phase 3 · registry result, not featured evidence · converted to % from 617 participants as posted
4.1% (n=4825) vs 5.5% (n=4825) placebo @ 265wk*b,c,d
NCT03914326 · Phase 3 · converted to % from 200 Participants as posted
Fasting Plasma Glucose Change mg/dL
absolute change · mg
-34.81 vs -34.25 Liraglutide mg @ 26wk1.5 mg weeklyb,c
NCT01624259 · Phase 3 · registry result, not featured evidence
-32.5 vs 0 placebo mg @ 26wk14 mga,b,c
NCT04109547 · Phase 3 · registry result, not featured evidence
show 2 more doses
-32.28 vs 0 placebo mg @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-19.07 vs 0 placebo mg @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1.5% (n=383) @ 52wk1.5 mga,b,c
NCT04809220 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.19% (n=193) @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-1.5% (n=497) @ 52wk14 mg once dailya,b,c
NCT04707469 · Phase 3 · registry result, not featured evidence
show 5 more doses
-0.4% (n=333) @ 52wk14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-2.1% (n=492) @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-1% (n=339) @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-1.9% (n=475) @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-0.8% (n=345) @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
71.48% (n=526) @ 36wk4.5 mga,b,c,e
NCT03495102 · Phase 3
show 2 more doses
64.68% (n=521) @ 36wk3 mg
NCT03495102 · Phase 3
56.98% (n=523) @ 36wk1.5 mg
NCT03495102 · Phase 3
39.2% (n=536) @ 68wk14 mg once dailya,b,c,e
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
58.9% (n=535) @ 68wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
49.9% (n=535) @ 68wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
HF Hospitalization or Urgent Visit
event count · % of participants
4.3% (n=4949) vs 4.6% (n=4952) placebo*b,c,f
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 213 Participants as posted
3% (n=4825) vs 3.5% (n=4825) placebo @ 265wk*b,c,f
NCT03914326 · Phase 3 · converted to % from 146 Participants as posted
Renal Composite
event rate · % of participants
6.7% (n=6579) vs 5.7% (n=6586) Tirzepatide @ 259wk*1.5 mgb,c,d
NCT04255433 · Phase 3 · registry result, not featured evidence · converted to % from 442 participants as posted
2.3% (n=4825) vs 2.7% (n=4825) placebo @ 265wk*b,c,d
NCT03914326 · Phase 3 · converted to % from 112 Participants as posted
Unstable Angina Hospitalization
event count · % of participants
1.8% (n=4949) vs 1.6% (n=4952) placebo*b,c,f
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 88 Participants as posted
1.5% (n=4825) vs 1.7% (n=4825) placebo @ 265wk*b,c,f
NCT03914326 · Phase 3 · converted to % from 74 Participants as posted
Weight
percent change · % of baseline
-4.82% (n=6578) vs -11.6% (n=6586) Tirzepatide @ 156wk1.5 mgb,c,g
NCT04255433 · Phase 3 · registry result, not featured evidence
-3.12% (n=93) vs -0.7% (n=97) Sitagliptin @ 104wkb,c,g
NCT02849080 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
No placebo or comparator arm
-0.5 kg @ 52wk1.5 mga,b,c
NCT04809220 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.2 kg @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-4.4 kg @ 52wk14 mg once dailya,b,c
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
-8.3 kg @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-7.1 kg @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
Dropout rate
0.3%h
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
4.4%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.8%4.5 mg
NCT03495102 · Phase 3
10.9%3 mg
NCT03495102 · Phase 3
9.2%1.5 mg
NCT03495102 · Phase 3
—1.5 mg
NCT01621178 · Phase 3
—0.75 mg
NCT01621178 · Phase 3
3.8%1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
3.9%0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
2.5%Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
—
NCT03315780 · Phase 4 · registry result, not featured evidence
2.2%1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
3.1%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
4.9%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
3.5%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
8%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
12.4%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
14.8%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
10.4%
NCT01769378 · Phase 3 · registry result, not featured evidence
9%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
9.7%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
—1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
10%LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
9.2%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
5.1%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
16.7%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
6.9%14 mgi
NCT02906930 · Phase 3
show 39 more results
8%7 mg
NCT02906930 · Phase 3
3.4%3 mg
NCT02906930 · Phase 3
2.7%14 mg
NCT02863328 · Phase 3
5.8%14 mg
NCT02607865 · Phase 3
6.4%7 mg
NCT02607865 · Phase 3
7.1%3 mg
NCT02607865 · Phase 3
2.8%14 mg
NCT02863419 · Phase 3
3.1%14 mg
NCT02827708 · Phase 3
3.3%14 mg
NCT03021187 · Phase 3
4.9%7 mg
NCT03021187 · Phase 3
5.4%3 mg
NCT03021187 · Phase 3
1.5%
NCT03914326 · Phase 3
0.3%
NCT02692716 · Phase 3
11.8%
NCT05035082 · Phase 4 · registry result, not featured evidence
5.4%14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
5.6%50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
8.4%25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
7.2%14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
5%7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.4%3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.6%14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
3.1%7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
3.1%3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
2.1%14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0%7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
6.1%3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
2.3%14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.5%7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
2.3%3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
11.3%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
11.4%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
5.7%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
7.1%20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
8.6%5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
4.3%2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—h
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
1.7%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.6%4.5 mg
NCT03495102 · Phase 3
1.1%3 mg
NCT03495102 · Phase 3
0.8%1.5 mg
NCT03495102 · Phase 3
—1.5 mg
NCT01621178 · Phase 3
—0.75 mg
NCT01621178 · Phase 3
1.9%1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
0%0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
1.7%Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
—
NCT03315780 · Phase 4 · registry result, not featured evidence
—1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
0%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
1.4%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
0%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
4%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
2.3%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
4.3%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
4.2%
NCT01769378 · Phase 3 · registry result, not featured evidence
2.5%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
0.4%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
—1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
6%LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
2.6%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
1.3%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
8.3%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
—14 mgi
NCT02906930 · Phase 3
show 39 more results
—7 mg
NCT02906930 · Phase 3
—3 mg
NCT02906930 · Phase 3
—14 mg
NCT02863328 · Phase 3
—14 mg
NCT02607865 · Phase 3
—7 mg
NCT02607865 · Phase 3
—3 mg
NCT02607865 · Phase 3
—14 mg
NCT02863419 · Phase 3
—14 mg
NCT02827708 · Phase 3
—14 mg
NCT03021187 · Phase 3
—7 mg
NCT03021187 · Phase 3
—3 mg
NCT03021187 · Phase 3
—
NCT03914326 · Phase 3
—
NCT02692716 · Phase 3
—
NCT05035082 · Phase 4 · registry result, not featured evidence
—14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
—14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Serious AEs
40.3%h
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
5%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.2%4.5 mg
NCT03495102 · Phase 3
7.3%3 mg
NCT03495102 · Phase 3
8.7%1.5 mg
NCT03495102 · Phase 3
21.4%1.5 mg
NCT01621178 · Phase 3
25.3%0.75 mg
NCT01621178 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
1.9%1.5 mg
NCT02963766 · Phase 3
4%1.5 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
2%0.75 mg
NCT02963766 · Phase 3
2%0.75 mg
NCT02963766 · Phase 3
0%1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
0%0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
2.5%0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
5%0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
0%
NCT03315780 · Phase 4 · registry result, not featured evidence
31.9%1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
3.8%1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
3.6%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
5.6%1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
3.5%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
2.1%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
6%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
9.3%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
5.8%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
3.8%
NCT01769378 · Phase 3 · registry result, not featured evidence
2.5%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
1.6%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
1.7%1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
—LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
3.9%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
8.9%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
3.7%1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
9.1%0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
0%Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
0%Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
0%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
1.1%14 mgi
NCT02906930 · Phase 3
show 39 more results
1.7%7 mg
NCT02906930 · Phase 3
2.9%3 mg
NCT02906930 · Phase 3
6.6%14 mg
NCT02863328 · Phase 3
9.5%14 mg
NCT02607865 · Phase 3
10.1%7 mg
NCT02607865 · Phase 3
13.7%3 mg
NCT02607865 · Phase 3
10.9%14 mg
NCT02863419 · Phase 3
10.4%14 mg
NCT02827708 · Phase 3
6.6%14 mg
NCT03021187 · Phase 3
10.5%7 mg
NCT03021187 · Phase 3
13.6%3 mg
NCT03021187 · Phase 3
47.9%
NCT03914326 · Phase 3
18.9%
NCT02692716 · Phase 3
10.2%
NCT05035082 · Phase 4 · registry result, not featured evidence
9.9%14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
8.2%50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
10.7%25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
3%14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
3.1%7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.4%3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
3.9%14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
7.7%7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
4.6%3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
9.5%Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
14.2%Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
9%Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
0%14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
6.1%7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
4.1%3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
5.4%14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
3%7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
6.9%3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.4%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
7.1%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
4.3%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
1.4%2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
h
nausea 14.9% (placebo 5.4%)
diarrhoea 13.5% (placebo 8.8%)
nasopharyngitis 11.4% (placebo 10.8%)
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 41 more results
nasopharyngitis 27.1%
diarrhoea 12.2%
nausea 9.4%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.5 mg
nausea 17.3%
diarrhoea 11.4%
vomiting 10.4%
NCT03495102 · Phase 3
3 mg
nausea 16.1%
diarrhoea 12.2%
vomiting 9.3%
NCT03495102 · Phase 3
1.5 mg
nausea 14.2%
diarrhoea 7.8%
vomiting 6.5%
NCT03495102 · Phase 3
1.5 mg
blood creatinine increased 38.5%
nausea 19.8%
diarrhoea 16.1%
NCT01621178 · Phase 3
0.75 mg
blood creatinine increased 37.4%
diarrhoea 15.8%
nausea 14.2%
NCT01621178 · Phase 3
1.5 mg
diarrhoea 21.2% (placebo 13.7%)
headache 15.4% (placebo 9.8%)
nausea 15.4% (placebo 7.8%)
NCT02963766 · Phase 3
1.5 mg
diarrhoea 12% (placebo 13.7%)
nausea 12% (placebo 7.8%)
abdominal pain upper 10% (placebo 7.8%)
NCT02963766 · Phase 3
0.75 mg
vomiting 17.6% (placebo 3.9%)
diarrhoea 15.7% (placebo 13.7%)
headache 13.7% (placebo 9.8%)
NCT02963766 · Phase 3
0.75 mg
headache 10.2% (placebo 9.8%)
vomiting 8.2% (placebo 3.9%)
abdominal pain 6.1% (placebo 5.9%)
NCT02963766 · Phase 3
1.5 mg
gastritis 14.3%
dyslipidaemia 9.5%
nausea 9.5%
NCT05659537 · Phase 4 · registry result, not featured evidence
0.75 mg
anaemia 21.4%
gastritis 14.3%
dyslipidaemia 7.1%
NCT05659537 · Phase 4 · registry result, not featured evidence
0.75 mg
nasopharyngitis 15.8% (placebo 30.8%)
abdominal discomfort 8.3% (placebo 12.8%)
constipation 6.7% (placebo 12.8%)
NCT02750410 · Phase 4 · registry result, not featured evidence
0.75 mg
nasopharyngitis 28.3% (placebo 30.8%)
constipation 10.8% (placebo 12.8%)
abdominal discomfort 9.2% (placebo 12.8%)
NCT02750410 · Phase 4 · registry result, not featured evidence
influenza 16.7% (placebo 0%)
decreased appetite 8.3% (placebo 0%)
diarrhoea 8.3% (placebo 8.3%)
NCT03315780 · Phase 4 · registry result, not featured evidence
1.5 mg
nausea 22.3%
diarrhoea 18.9%
covid-19 15.1%
NCT04255433 · Phase 3 · registry result, not featured evidence
1.5 mg
constipation 12.5%
diarrhoea 10.2%
pyrexia 10%
NCT04809220 · Phase 3 · registry result, not featured evidence
0.75 mg
constipation 8.7%
nasopharyngitis 8.7%
covid-19 8.2%
NCT04809220 · Phase 3 · registry result, not featured evidence
1.5 mg
decreased appetite 22.2% (placebo 4.1%)
diabetic nephropathy 13.9% (placebo 15%)
diarrhoea 13.2% (placebo 8.2%)
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
1.5 mg
nausea 14.8% (placebo 3.6%)
back pain 9.2% (placebo 7.1%)
viral upper respiratory tract infection 6.3% (placebo 7.9%)
NCT02597049 · Phase 3 · registry result, not featured evidence
0.75 mg
diarrhoea 9.9% (placebo 2.9%)
back pain 8.5% (placebo 7.1%)
viral upper respiratory tract infection 5.7% (placebo 7.9%)
NCT02597049 · Phase 3 · registry result, not featured evidence
nausea 12% (placebo 1.3%)
diarrhoea 11.3% (placebo 4%)
upper respiratory tract infection 7.3% (placebo 6.7%)
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
hyperlipidaemia 17.8%
diarrhoea 16.7%
lipase increased 10.5%
NCT01648582 · Phase 3 · registry result, not featured evidence
0.75 mg
hyperlipidaemia 19.5%
diarrhoea 10.9%
hypertension 10.9%
NCT01648582 · Phase 3 · registry result, not featured evidence
nausea 10.5% (placebo 0%)
diarrhoea 8.4% (placebo 0%)
eructation 5.9% (placebo 0%)
NCT01769378 · Phase 3 · registry result, not featured evidence
1.5 mg
diarrhoea 17.2%
hyperlipidaemia 11.1%
nausea 10.2%
NCT01644500 · Phase 3 · registry result, not featured evidence
0.75 mg
hyperlipidaemia 12.1%
diarrhoea 7.3%
lipase increased 5.6%
NCT01644500 · Phase 3 · registry result, not featured evidence
1.5 mg weekly
nausea 20.4%
diarrhoea 12%
dyspepsia 8%
NCT01624259 · Phase 3 · registry result, not featured evidence
4.5 mg
nausea 30.3% (placebo 4.9%)
diarrhoea 21.1% (placebo 11.1%)
vomiting 13.2% (placebo 4.9%)
NCT02973100 · Phase 2 · registry result, not featured evidence
3.0 mg
nausea 25.3% (placebo 4.9%)
diarrhoea 22.8% (placebo 11.1%)
decreased appetite 16.5% (placebo 1.2%)
NCT02973100 · Phase 2 · registry result, not featured evidence
1.5 mg
nausea 22.2% (placebo 4.9%)
diarrhoea 11.1% (placebo 11.1%)
vomiting 11.1% (placebo 4.9%)
NCT02973100 · Phase 2 · registry result, not featured evidence
1.5 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
blood pressure decreased 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
1.5 mg
abdominal discomfort 10% (placebo 6.3%)
decreased appetite 10% (placebo 0%)
nausea 10% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.75 mg
abdominal discomfort 9.1% (placebo 6.3%)
nausea 9.1% (placebo 0%)
vomiting 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.75 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
abdominal distension 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.5 mg
abdominal discomfort 0% (placebo 6.3%)
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.5 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
abdominal pain 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
headache 41.2%
nausea 41.2%
vomiting 35.3%
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 8%
haemorrhoids 4%
injection site pain 4%
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
vomiting 11.5%
decreased appetite 7.7%
headache 7.7%
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
gastrooesophageal reflux disease 33.3%
atrioventricular block first degree 28.6%
headache 28.6%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
14 mgi
nausea 16% (placebo 5.6%)
vomiting 6.9% (placebo 2.2%)
decreased appetite 5.1% (placebo 0.6%)
NCT02906930 · Phase 3
show 38 more results
7 mg
nasopharyngitis 6.3% (placebo 3.4%)
headache 5.7% (placebo 5.1%)
diarrhoea 5.1% (placebo 2.2%)
NCT02906930 · Phase 3
3 mg
diarrhoea 8.6% (placebo 2.2%)
nausea 8% (placebo 5.6%)
nasopharyngitis 5.7% (placebo 3.4%)
NCT02906930 · Phase 3
14 mg
nausea 19.8%
diarrhoea 9.3%
vomiting 7.3%
NCT02863328 · Phase 3
14 mg
nausea 15.1%
diarrhoea 12%
nasopharyngitis 10.1%
NCT02607865 · Phase 3
7 mg
nausea 13.4%
diarrhoea 11.4%
nasopharyngitis 10.6%
NCT02607865 · Phase 3
3 mg
nasopharyngitis 11.4%
diarrhoea 9.4%
upper respiratory tract infection 7.7%
NCT02607865 · Phase 3
14 mg
nausea 19.3% (placebo 3.5%)
diarrhoea 15.1% (placebo 7.7%)
nasopharyngitis 14.4% (placebo 10.6%)
NCT02863419 · Phase 3
14 mg
nausea 19% (placebo 7.5%)
constipation 11.7% (placebo 3.7%)
vomiting 11.7% (placebo 1.2%)
NCT02827708 · Phase 3
14 mg
nausea 22.7% (placebo 7.1%)
diarrhoea 14.4% (placebo 6%)
decreased appetite 12.7% (placebo 1.1%)
NCT03021187 · Phase 3
7 mg
nausea 16.6% (placebo 7.1%)
diarrhoea 12.2% (placebo 6%)
nasopharyngitis 11.6% (placebo 14.7%)
NCT03021187 · Phase 3
3 mg
nasopharyngitis 14.7% (placebo 14.7%)
nausea 11.4% (placebo 7.1%)
diarrhoea 8.7% (placebo 6%)
NCT03021187 · Phase 3
diabetic retinopathy 19.5% (placebo 19.3%)
covid-19 15.7% (placebo 16.1%)
nausea 7.1% (placebo 1.3%)
NCT03914326 · Phase 3
covid-19 8.8%
nausea 7.6%
NCT05035082 · Phase 4 · registry result, not featured evidence
14 mg once daily
nausea 18%
diarrhoea 12.4%
covid-19 11.8%
NCT04707469 · Phase 3 · registry result, not featured evidence
50 mg once daily
nausea 27.3%
vomiting 18.2%
diarrhoea 14.2%
NCT04707469 · Phase 3 · registry result, not featured evidence
25 mg once daily
nausea 27.2%
vomiting 17%
diarrhoea 12.9%
NCT04707469 · Phase 3 · registry result, not featured evidence
14 mg
diarrhoea 13.3%
nausea 12.2%
decreased appetite 9.4%
NCT04017832 · Phase 3 · registry result, not featured evidence
7 mg
nausea 10.9%
diarrhoea 8.9%
decreased appetite 8.4%
NCT04017832 · Phase 3 · registry result, not featured evidence
3 mg
nausea 10%
diarrhoea 8.3%
upper respiratory tract infection 7.2%
NCT04017832 · Phase 3 · registry result, not featured evidence
14 mg
decreased appetite 10.9% (placebo 0%)
diarrhoea 9.3% (placebo 1.5%)
upper respiratory tract infection 7% (placebo 4.6%)
NCT04109547 · Phase 3 · registry result, not featured evidence
7 mg
diarrhoea 9.2% (placebo 1.5%)
upper respiratory tract infection 9.2% (placebo 4.6%)
lipase increased 8.5% (placebo 0%)
NCT04109547 · Phase 3 · registry result, not featured evidence
3 mg
upper respiratory tract infection 8.5% (placebo 4.6%)
lipase increased 5.4% (placebo 0%)
nausea 4.6% (placebo 1.5%)
NCT04109547 · Phase 3 · registry result, not featured evidence
nausea 20.9%
nasopharyngitis 10.3%
headache 9.9%
NCT02849080 · Phase 3 · registry result, not featured evidence
nausea 22.9%
nasopharyngitis 13.4%
diarrhoea 11.5%
NCT02849080 · Phase 3 · registry result, not featured evidence
nausea 17%
diarrhoea 10%
nasopharyngitis 7%
NCT02849080 · Phase 3 · registry result, not featured evidence
14 mg
nasopharyngitis 18.8% (placebo 28.6%)
constipation 12.5% (placebo 6.1%)
decreased appetite 12.5% (placebo 0%)
NCT03018028 · Phase 3 · registry result, not featured evidence
7 mg
nasopharyngitis 16.3% (placebo 28.6%)
constipation 12.2% (placebo 6.1%)
nausea 10.2% (placebo 2%)
NCT03018028 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 20.4% (placebo 28.6%)
constipation 10.2% (placebo 6.1%)
periarthritis 10.2% (placebo 4.1%)
NCT03018028 · Phase 3 · registry result, not featured evidence
14 mg
nasopharyngitis 30%
constipation 15.4%
nausea 9.2%
NCT03015220 · Phase 3 · registry result, not featured evidence
7 mg
nasopharyngitis 29.5%
constipation 12.1%
decreased appetite 9.1%
NCT03015220 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 26%
constipation 9.2%
influenza 6.9%
NCT03015220 · Phase 3 · registry result, not featured evidence
40 mg
nausea 33.8% (placebo 1.4%)
vomiting 19.7% (placebo 4.2%)
decreased appetite 14.1% (placebo 1.4%)
NCT01923181 · Phase 2 · registry result, not featured evidence
40 mg
nausea 35.7% (placebo 1.4%)
vomiting 22.9% (placebo 4.2%)
diarrhoea 17.1% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence
40 mg
nausea 32.9% (placebo 1.4%)
diarrhoea 20% (placebo 9.9%)
vomiting 15.7% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
20 mg
nausea 35.7% (placebo 1.4%)
diarrhoea 20% (placebo 9.9%)
vomiting 17.1% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
10 mg
nausea 33.3% (placebo 1.4%)
diarrhoea 23.2% (placebo 9.9%)
vomiting 20.3% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
5 mg
nausea 14.3% (placebo 1.4%)
headache 12.9% (placebo 5.6%)
diarrhoea 10% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence
2.5 mg
nausea 12.9% (placebo 1.4%)
nasopharyngitis 8.6% (placebo 12.7%)
diarrhoea 7.1% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 259 weeks versus 265 weeks.
  5. eAssessment timepoints differ: 36 weeks versus 68 weeks.
  6. fThe assessment timepoint is not available for both results.
  7. gAssessment timepoints differ: 156 weeks versus 104 weeks.
  8. hPopulation comparability has not been reviewed for 44 of these studies.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

dulaglutide

Microvascular Composite 22.2% (n=4949) vs 25.1% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 1099 Participants as posted
HbA1c Less Than or Equal to 6.5 51.1% (n=178) vs 24% (n=179) Insulin Glargine @ 26wk
responder rate · % of participants
HbA1c <=6.5%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 71.3% (n=178) vs 45.8% (n=179) Insulin Glargine @ 26wk
responder rate · % of participants
HbA1c <7%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
FBG -34.3 vs -37.8 Insulin Glargine mg @ 26wk
absolute change · mg
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Serum Glucose Change mg/dL -52.3 mg @ 36wk4.5 mg
absolute change · mg
No placebo or comparator arm
NCT03495102 · Phase 3
show 4 more results
-47.9 mg @ 36wk3 mg
NCT03495102 · Phase 3
-44.2 mg @ 36wk1.5 mg
NCT03495102 · Phase 3
-42.4 mg @ 52wk1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-33.1 mg @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 68.2% (n=66) vs 20% (n=70) placebo @ 18wk4.5 mg
responder rate · % of participants
NCT02973100 · Phase 2 · registry result, not featured evidence
show 8 more results
71.2% (n=73) vs 20% (n=70) placebo @ 18wk3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
37.5% (n=152) vs 34.6% (n=182) Insulin Glargine @ 26wk1.5 mg
NCT01621178 · Phase 3
32.9% (n=152) vs 29.1% (n=182) Insulin Glargine @ 52wk1.5 mg
NCT01621178 · Phase 3
75.9% (n=133) vs 33.8% (n=142) placebo @ 28wk1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
71.2% (n=73) vs 20% (n=70) placebo @ 18wk1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
31.7% (n=164) vs 34.6% (n=182) Insulin Glargine @ 26wk0.75 mg
NCT01621178 · Phase 3
33.5% (n=164) vs 29.1% (n=182) Insulin Glargine @ 52wk0.75 mg
NCT01621178 · Phase 3
0% (n=116) vs 47.4% (n=36) placebo @ 16wk
NCT02750410 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 8 78.3% (n=152) vs 75.3% (n=182) Insulin Glargine @ 26wk1.5 mg
responder rate · % of participants
NCT01621178 · Phase 3
show 3 more results
69.1% (n=152) vs 70.3% (n=182) Insulin Glargine @ 52wk1.5 mg
NCT01621178 · Phase 3
72.6% (n=164) vs 75.3% (n=182) Insulin Glargine @ 26wk0.75 mg
NCT01621178 · Phase 3
69.5% (n=164) vs 70.3% (n=182) Insulin Glargine @ 52wk0.75 mg
NCT01621178 · Phase 3
SMBG 8-point Change mg/dL -33.7 vs -37.6 Insulin Glargine mg @ 26wk1.5 mg
absolute change · mg
NCT01621178 · Phase 3
show 1 more result
-31.7 vs -37.6 Insulin Glargine mg @ 26wk0.75 mg
NCT01621178 · Phase 3
Fasting Glucose Change mg/dL 23.1 vs -19.1 Insulin Glargine mg @ 26wk1.5 mg
absolute change · mg
NCT01621178 · Phase 3
show 2 more results
17.7 vs -19.1 Insulin Glargine mg @ 26wk0.75 mg
NCT01621178 · Phase 3
-44.63 vs -27.9 placebo mg @ 28wk
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
Daily Insulin Dose 18.12 vs 16.64 Insulin Glargine per day @ 26wk1.5 mg
absolute change · per day
NCT01621178 · Phase 3
show 4 more results
20.05 vs 16.84 Insulin Glargine per day @ 52wk1.5 mg
NCT01621178 · Phase 3
26.16 vs 16.64 Insulin Glargine per day @ 26wk0.75 mg
NCT01621178 · Phase 3
27.46 vs 16.84 Insulin Glargine per day @ 52wk0.75 mg
NCT01621178 · Phase 3
-1.1 vs -0.3 placebo per day @ 16wk
NCT02750410 · Phase 4 · registry result, not featured evidence
Serum Creatinine Change mg/dL 0.04 vs 0.1 Insulin Glargine mg/dL @ 26wk1.5 mg
absolute change · mg/dL
NCT01621178 · Phase 3
show 3 more results
0.07 vs 0.12 Insulin Glargine mg/dL @ 52wk1.5 mg
NCT01621178 · Phase 3
0.02 vs 0.1 Insulin Glargine mg/dL @ 26wk0.75 mg
NCT01621178 · Phase 3
0.04 vs 0.12 Insulin Glargine mg/dL @ 52wk0.75 mg
NCT01621178 · Phase 3
eGFR -1 vs -2.5 Insulin Glargine mL @ 26wk1.5 mg
absolute change · mL
NCT01621178 · Phase 3
show 3 more results
-2 vs -3.3 Insulin Glargine mL @ 52wk1.5 mg
NCT01621178 · Phase 3
-1 vs -2.5 Insulin Glargine mL @ 26wk0.75 mg
NCT01621178 · Phase 3
-1.5 vs -3.3 Insulin Glargine mL @ 52wk0.75 mg
NCT01621178 · Phase 3

+ 51 further endpoints in the CSV export.

Semaglutide (Rybelsus)

HbA1c -1.5% (n=175) vs -0.3% (n=178) placebo @ 26wk14 mg
absolute change · percentage points
In-trial
NCT02906930 · Phase 3
show 11 more results
-1.3% (n=411) vs -0.9% (n=410) Empagliflozin 25 mg @ 26wk14 mg
In-trial
NCT02863328 · Phase 3
-1.3% (n=465) vs -0.8% (n=467) Sitagliptin @ 26wk14 mg
In-trial
NCT02607865 · Phase 3
-1.2% (n=285) vs -0.1% (n=142) placebo @ 26wk14 mg
In-trial
NCT02863419 · Phase 3
-1.1% (n=163) vs -0.2% (n=161) placebo @ 26wk14 mg
In-trial
NCT02827708 · Phase 3
-1.3% (n=181) vs -0.1% (n=184) placebo @ 26wk14 mg
In-trial
NCT03021187 · Phase 3
-1.3% (n=175) vs -0.3% (n=178) placebo @ 26wk7 mg
In-trial
NCT02906930 · Phase 3
-1.1% (n=465) vs -0.8% (n=467) Sitagliptin @ 26wk7 mg
In-trial
NCT02607865 · Phase 3
-1% (n=182) vs -0.1% (n=184) placebo @ 26wk7 mg
In-trial
NCT03021187 · Phase 3
-0.9% (n=175) vs -0.3% (n=178) placebo @ 26wk3 mg
In-trial
NCT02906930 · Phase 3
-0.6% (n=466) vs -0.8% (n=467) Sitagliptin @ 26wk3 mg
In-trial
NCT02607865 · Phase 3
-0.5% (n=184) vs -0.1% (n=184) placebo @ 26wk3 mg
In-trial
NCT03021187 · Phase 3
Weight -4 vs -1.4 placebo kg @ 26wk14 mg
absolute change · kg
In-trial
NCT02906930 · Phase 3
show 9 more results
-3.9 vs -3.8 Empagliflozin 25 mg kg @ 26wk14 mg
In-trial
NCT02863328 · Phase 3
-3.1 vs -0.6 Sitagliptin kg @ 26wk14 mg
In-trial
NCT02607865 · Phase 3
-4.4 vs -0.6 placebo kg @ 26wk14 mg
In-trial
NCT02863419 · Phase 3
-3.5 vs -0.9 placebo kg @ 26wk14 mg
In-trial
NCT02827708 · Phase 3
-2.6 vs -1.4 placebo kg @ 26wk7 mg
In-trial
NCT02906930 · Phase 3
-2.2 vs -0.6 Sitagliptin kg @ 26wk7 mg
In-trial
NCT02607865 · Phase 3
-1.5 vs -1.4 placebo kg @ 26wk3 mg
In-trial
NCT02906930 · Phase 3
-1.2 vs -0.6 Sitagliptin kg @ 26wk3 mg
In-trial
NCT02607865 · Phase 3
-2.7 vs -0.7 Sitagliptin kg @ 52wk
In-trial
NCT02849080 · Phase 3 · registry result, not featured evidence
SMBG 7-point -2.3 vs -0.5 placebo mmol/L @ 26wk14 mg
absolute change · mmol/L
NCT02906930 · Phase 3
show 36 more results
-2.3 vs -1.9 Empagliflozin 25 mg mmol/L @ 26wk14 mg
NCT02863328 · Phase 3
-2.3 vs -2.1 Empagliflozin 25 mg mmol/L @ 52wk14 mg
NCT02863328 · Phase 3
-1.7 vs -1.2 Sitagliptin mmol/L @ 26wk14 mg
NCT02607865 · Phase 3
-1.8 vs -1.4 Sitagliptin mmol/L @ 52wk14 mg
NCT02607865 · Phase 3
-1.7 vs -1.3 Sitagliptin mmol/L @ 78wk14 mg
NCT02607865 · Phase 3
-2.2 vs -0.7 placebo mmol/L @ 26wk14 mg
NCT02863419 · Phase 3
-2.2 vs -0.9 placebo mmol/L @ 52wk14 mg
NCT02863419 · Phase 3
-2 vs -0.3 placebo mmol/L @ 26wk14 mg
NCT03021187 · Phase 3
-2 vs -0.9 placebo mmol/L @ 52wk14 mg
NCT03021187 · Phase 3
-2.6 vs -1.2 Sitagliptin mmol/L @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-3.1 vs -0.8 placebo mmol/L @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-3.1 vs 0 placebo mmol/L @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.9 Dulaglutide mmol/L @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 Dulaglutide mmol/L @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.1 vs -0.5 placebo mmol/L @ 26wk7 mg
NCT02906930 · Phase 3
-1.5 vs -1.2 Sitagliptin mmol/L @ 26wk7 mg
NCT02607865 · Phase 3
-1.5 vs -1.4 Sitagliptin mmol/L @ 52wk7 mg
NCT02607865 · Phase 3
-1.5 vs -1.3 Sitagliptin mmol/L @ 78wk7 mg
NCT02607865 · Phase 3
-1.8 vs -0.3 placebo mmol/L @ 26wk7 mg
NCT03021187 · Phase 3
-1.7 vs -0.9 placebo mmol/L @ 52wk7 mg
NCT03021187 · Phase 3
-2.3 vs -1.2 Sitagliptin mmol/L @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2.6 vs -0.8 placebo mmol/L @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-2.2 vs 0 placebo mmol/L @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-2.7 vs -2.9 Dulaglutide mmol/L @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.6 Dulaglutide mmol/L @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-1.8 vs -0.5 placebo mmol/L @ 26wk3 mg
NCT02906930 · Phase 3
-1.1 vs -1.2 Sitagliptin mmol/L @ 26wk3 mg
NCT02607865 · Phase 3
-1.3 vs -1.4 Sitagliptin mmol/L @ 52wk3 mg
NCT02607865 · Phase 3
-1.3 vs -1.3 Sitagliptin mmol/L @ 78wk3 mg
NCT02607865 · Phase 3
-1.2 vs -0.3 placebo mmol/L @ 26wk3 mg
NCT03021187 · Phase 3
-1.6 vs -0.9 placebo mmol/L @ 52wk3 mg
NCT03021187 · Phase 3
-1.5 vs -1.2 Sitagliptin mmol/L @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2.2 vs -0.8 placebo mmol/L @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.7 vs 0 placebo mmol/L @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.8 vs -2.9 Dulaglutide mmol/L @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-1.7 vs -2.6 Dulaglutide mmol/L @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
PPG Excursion -1.2 vs -0.3 placebo mmol/L @ 26wk14 mg
absolute change · mmol/L
NCT02906930 · Phase 3
show 36 more results
-0.5 vs -0.4 Empagliflozin 25 mg mmol/L @ 26wk14 mg
NCT02863328 · Phase 3
-0.6 vs -0.4 Empagliflozin 25 mg mmol/L @ 52wk14 mg
NCT02863328 · Phase 3
-0.6 vs -0.6 Sitagliptin mmol/L @ 26wk14 mg
NCT02607865 · Phase 3
-0.7 vs -0.4 Sitagliptin mmol/L @ 52wk14 mg
NCT02607865 · Phase 3
-0.6 vs -0.6 Sitagliptin mmol/L @ 78wk14 mg
NCT02607865 · Phase 3
-0.7 vs -0.2 placebo mmol/L @ 26wk14 mg
NCT02863419 · Phase 3
-0.5 vs -0.4 placebo mmol/L @ 52wk14 mg
NCT02863419 · Phase 3
-1.2 vs -0.1 placebo mmol/L @ 26wk14 mg
NCT03021187 · Phase 3
-0.7 vs -0.3 placebo mmol/L @ 52wk14 mg
NCT03021187 · Phase 3
-1 vs -0.6 Sitagliptin mmol/L @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2 vs -0.5 placebo mmol/L @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-2 vs -0.1 placebo mmol/L @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.7 Dulaglutide mmol/L @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.7 Dulaglutide mmol/L @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.3 placebo mmol/L @ 26wk7 mg
NCT02906930 · Phase 3
-0.4 vs -0.6 Sitagliptin mmol/L @ 26wk7 mg
NCT02607865 · Phase 3
-0.4 vs -0.4 Sitagliptin mmol/L @ 52wk7 mg
NCT02607865 · Phase 3
-0.4 vs -0.6 Sitagliptin mmol/L @ 78wk7 mg
NCT02607865 · Phase 3
-0.8 vs -0.1 placebo mmol/L @ 26wk7 mg
NCT03021187 · Phase 3
-0.7 vs -0.3 placebo mmol/L @ 52wk7 mg
NCT03021187 · Phase 3
-0.9 vs -0.6 Sitagliptin mmol/L @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.5 placebo mmol/L @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.1 placebo mmol/L @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.3 vs -0.7 Dulaglutide mmol/L @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.7 Dulaglutide mmol/L @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.3 placebo mmol/L @ 26wk3 mg
NCT02906930 · Phase 3
-0.4 vs -0.6 Sitagliptin mmol/L @ 26wk3 mg
NCT02607865 · Phase 3
-0.4 vs -0.4 Sitagliptin mmol/L @ 52wk3 mg
NCT02607865 · Phase 3
-0.4 vs -0.6 Sitagliptin mmol/L @ 78wk3 mg
NCT02607865 · Phase 3
-0.3 vs -0.1 placebo mmol/L @ 26wk3 mg
NCT03021187 · Phase 3
-0.3 vs -0.3 placebo mmol/L @ 52wk3 mg
NCT03021187 · Phase 3
-0.4 vs -0.6 Sitagliptin mmol/L @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.5 placebo mmol/L @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.5 vs -0.1 placebo mmol/L @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.7 Dulaglutide mmol/L @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.7 Dulaglutide mmol/L @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Waist Circumference Change -4.1 vs -0.9 placebo cm @ 26wk14 mg
absolute change · cm
NCT02906930 · Phase 3
show 49 more results
-3.9 vs -2.9 Empagliflozin 25 mg cm @ 26wk14 mg
NCT02863328 · Phase 3
-3.7 vs -2.9 Empagliflozin 25 mg cm @ 52wk14 mg
NCT02863328 · Phase 3
-2.3 vs -0.6 Sitagliptin cm @ 26wk14 mg
NCT02607865 · Phase 3
-2.6 vs -0.5 Sitagliptin cm @ 52wk14 mg
NCT02607865 · Phase 3
-2.4 vs -0.7 Sitagliptin cm @ 78wk14 mg
NCT02607865 · Phase 3
-4.2 vs -1.2 placebo cm @ 26wk14 mg
NCT02863419 · Phase 3
-4.4 vs -1.7 placebo cm @ 52wk14 mg
NCT02863419 · Phase 3
-2.8 vs -0.7 placebo cm @ 26wk14 mg
NCT02827708 · Phase 3
-3.6 vs -0.6 placebo cm @ 26wk14 mg
NCT03021187 · Phase 3
-4 vs 0.3 placebo cm @ 52wk14 mg
NCT03021187 · Phase 3
-3.7 vs -0.8 Sitagliptin cm @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2.8 vs -1.4 placebo cm @ 26wk14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-1.3 vs -0.5 placebo cm @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-2.7 vs -0.9 placebo cm @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.2 vs 0.3 Dulaglutide cm @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-1.7 vs 0.7 Dulaglutide cm @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.3 vs -0.9 placebo cm @ 26wk7 mg
NCT02906930 · Phase 3
-1.8 vs -0.6 Sitagliptin cm @ 26wk7 mg
NCT02607865 · Phase 3
-2.3 vs -0.5 Sitagliptin cm @ 52wk7 mg
NCT02607865 · Phase 3
-2.4 vs -0.7 Sitagliptin cm @ 78wk7 mg
NCT02607865 · Phase 3
-2.3 vs -0.6 placebo cm @ 26wk7 mg
NCT03021187 · Phase 3
-2.3 vs 0.3 placebo cm @ 52wk7 mg
NCT03021187 · Phase 3
-2.7 vs -0.8 Sitagliptin cm @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2.2 vs -1.4 placebo cm @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.5 placebo cm @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1 vs -0.9 placebo cm @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.6 vs 0.3 Dulaglutide cm @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.8 vs 0.7 Dulaglutide cm @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2 vs -0.9 placebo cm @ 26wk3 mg
NCT02906930 · Phase 3
-0.7 vs -0.6 Sitagliptin cm @ 26wk3 mg
NCT02607865 · Phase 3
-1.3 vs -0.5 Sitagliptin cm @ 52wk3 mg
NCT02607865 · Phase 3
-1.2 vs -0.7 Sitagliptin cm @ 78wk3 mg
NCT02607865 · Phase 3
-0.9 vs -0.6 placebo cm @ 26wk3 mg
NCT03021187 · Phase 3
-0.8 vs 0.3 placebo cm @ 52wk3 mg
NCT03021187 · Phase 3
-1.6 vs -0.8 Sitagliptin cm @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2.1 vs -1.4 placebo cm @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0.5 vs -0.5 placebo cm @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.2 vs -0.9 placebo cm @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0 vs 0.3 Dulaglutide cm @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.1 vs 0.7 Dulaglutide cm @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-5.71 vs -2.29 placebo cm @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-4.86 vs -2.29 placebo cm @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-6.24 vs -2.29 placebo cm @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-4.08 vs -2.29 placebo cm @ 26wk20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-5.28 vs -2.29 placebo cm @ 26wk10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-2.29 vs -2.29 placebo cm @ 26wk5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-2 vs -2.29 placebo cm @ 26wk2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-2.6 vs -0.7 Sitagliptin cm @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
-1.8 vs -0.9 Sitagliptin cm @ 104wk
NCT02849080 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 76.9% (n=160) vs 31% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 123 Participants as posted
show 10 more results
57.8% (n=154) vs 22.6% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 89 Participants as posted
75.8% (n=298) vs 36.5% (n=334) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 226 Participants as posted
79.3% (n=116) vs 25.5% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 92 Participants as posted
68.8% (n=160) vs 31% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 110 Participants as posted
67.6% (n=315) vs 36.5% (n=334) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 213 Participants as posted
85.5% (n=117) vs 25.5% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 100 Participants as posted
55.1% (n=167) vs 31% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 92 Participants as posted
43.3% (n=321) vs 36.5% (n=334) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 139 Participants as posted
65.8% (n=114) vs 25.5% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 75 Participants as posted
58.3% (n=326) vs 45.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 190 Participants as posted
HbA1c 6.5 or Less 63.8% (n=160) vs 17.9% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 102 Participants as posted
show 2 more results
47.5% (n=160) vs 17.9% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 76 Participants as posted
35.9% (n=167) vs 17.9% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 60 Participants as posted
Weight Loss 5% 41.3% (n=160) vs 14.9% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 66 Participants as posted
show 11 more results
35.7% (n=154) vs 9.7% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 55 Participants as posted
44.7% (n=333) vs 8% (n=351) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 149 Participants as posted
37.1% (n=116) vs 10.4% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
26.9% (n=160) vs 14.9% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 43 Participants as posted
31.3% (n=342) vs 8% (n=351) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted
24.4% (n=119) vs 10.4% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
19.6% (n=168) vs 14.9% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 33 Participants as posted
16% (n=343) vs 8% (n=351) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 55 Participants as posted
14.8% (n=115) vs 10.4% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 17 Participants as posted
36.9% (n=298) vs 31.9% (n=260) Other Oral Glucose-lowering Medication @ 52wk*
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 110 Participants as posted
27% (n=233) vs 12.1% (n=239) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 63 Participants as posted
Weight Loss 10% 14.4% (n=160) vs 1.2% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 23 Participants as posted
show 10 more results
8.4% (n=154) vs 0% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 13 Participants as posted
12.6% (n=333) vs 0.6% (n=351) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 42 Participants as posted
10.3% (n=116) vs 0% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 12 Participants as posted
8.1% (n=160) vs 1.2% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 13 Participants as posted
7% (n=342) vs 0.6% (n=351) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
5.9% (n=119) vs 0% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
2.4% (n=168) vs 1.2% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 4 Participants as posted
1.5% (n=343) vs 0.6% (n=351) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
4.3% (n=115) vs 0% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
6.4% (n=233) vs 2.1% (n=239) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain 68.8% (n=160) vs 23.2% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 110 Participants as posted
show 10 more results
50.6% (n=154) vs 17.4% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 78 Participants as posted
66.9% (n=332) vs 22.6% (n=350) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 222 Participants as posted
72.4% (n=116) vs 17.9% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 84 Participants as posted
56.9% (n=160) vs 23.2% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 91 Participants as posted
57.5% (n=339) vs 22.6% (n=350) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 195 Participants as posted
68.4% (n=117) vs 17.9% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
37.1% (n=167) vs 23.2% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 62 Participants as posted
33.1% (n=344) vs 22.6% (n=350) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 114 Participants as posted
47.4% (n=114) vs 17.9% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 54 Participants as posted
45.2% (n=230) vs 14.7% (n=238) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 104 Participants as posted
HbA1c Reduction 1% and Weight Loss 3% 50.6% (n=160) vs 10.7% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 81 Participants as posted
show 10 more results
39% (n=154) vs 7.7% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 60 Participants as posted
47.9% (n=332) vs 9.4% (n=350) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 159 Participants as posted
45.7% (n=116) vs 9.4% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 53 Participants as posted
36.9% (n=160) vs 10.7% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 59 Participants as posted
37.8% (n=339) vs 9.4% (n=350) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 128 Participants as posted
36.8% (n=117) vs 9.4% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
18% (n=167) vs 10.7% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 30 Participants as posted
18.6% (n=344) vs 9.4% (n=350) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 64 Participants as posted
22.8% (n=114) vs 9.4% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 26 Participants as posted
34.8% (n=230) vs 10.5% (n=238) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
Time to Additional Anti-diabetic Medication 4% (n=175) vs 19.7% (n=178) placebo14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 7 Participants as posted
show 36 more results
4.1% (n=411) vs 3.2% (n=410) Empagliflozin 25 mg @ 26wk*14 mg
NCT02863328 · Phase 3 · converted to % from 17 Participants as posted
12.7% (n=411) vs 13.7% (n=410) Empagliflozin 25 mg @ 52wk*14 mg
NCT02863328 · Phase 3 · converted to % from 52 Participants as posted
3.2% (n=465) vs 4.3% (n=467) Sitagliptin @ 26wk*14 mg
NCT02607865 · Phase 3 · converted to % from 15 Participants as posted
11% (n=465) vs 23.8% (n=467) Sitagliptin @ 52wk*14 mg
NCT02607865 · Phase 3 · converted to % from 51 Participants as posted
16.1% (n=465) vs 31.7% (n=467) Sitagliptin @ 78wk*14 mg
NCT02607865 · Phase 3 · converted to % from 75 Participants as posted
7% (n=285) vs 8.5% (n=142) placebo @ 26wk*14 mg
NCT02863419 · Phase 3 · converted to % from 20 Participants as posted
13.7% (n=285) vs 32.4% (n=142) placebo @ 52wk*14 mg
NCT02863419 · Phase 3 · converted to % from 39 Participants as posted
7.4% (n=163) vs 13% (n=161) placebo*14 mg
NCT02827708 · Phase 3 · converted to % from 12 Participants as posted
4.4% (n=181) vs 6% (n=184) placebo @ 26wk*14 mg
NCT03021187 · Phase 3 · converted to % from 8 Participants as posted
24.3% (n=181) vs 40.8% (n=184) placebo @ 52wk*14 mg
NCT03021187 · Phase 3 · converted to % from 44 Participants as posted
2.1% (n=48) vs 14.3% (n=49) placebo @ 26wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
8.3% (n=48) vs 30.6% (n=49) placebo @ 52wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
4.6% (n=130) vs 1.5% (n=65) Dulaglutide @ 26wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
6.2% (n=130) vs 12.3% (n=65) Dulaglutide @ 52wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
4.6% (n=175) vs 19.7% (n=178) placebo*7 mg
NCT02906930 · Phase 3 · converted to % from 8 Participants as posted
4.3% (n=465) vs 4.3% (n=467) Sitagliptin @ 26wk*7 mg
NCT02607865 · Phase 3 · converted to % from 20 Participants as posted
18.5% (n=465) vs 23.8% (n=467) Sitagliptin @ 52wk*7 mg
NCT02607865 · Phase 3 · converted to % from 86 Participants as posted
25.6% (n=465) vs 31.7% (n=467) Sitagliptin @ 78wk*7 mg
NCT02607865 · Phase 3 · converted to % from 119 Participants as posted
4.4% (n=182) vs 6% (n=184) placebo @ 26wk*7 mg
NCT03021187 · Phase 3 · converted to % from 8 Participants as posted
24.7% (n=182) vs 40.8% (n=184) placebo @ 52wk*7 mg
NCT03021187 · Phase 3 · converted to % from 45 Participants as posted
6.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
12.2% (n=49) vs 30.6% (n=49) placebo @ 52wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
2.3% (n=132) vs 1.5% (n=65) Dulaglutide @ 26wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
9.8% (n=132) vs 12.3% (n=65) Dulaglutide @ 52wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 13 Participants as posted
9.1% (n=175) vs 19.7% (n=178) placebo*3 mg
NCT02906930 · Phase 3 · converted to % from 16 Participants as posted
7.1% (n=466) vs 4.3% (n=467) Sitagliptin @ 26wk*3 mg
NCT02607865 · Phase 3 · converted to % from 33 Participants as posted
29.4% (n=466) vs 23.8% (n=467) Sitagliptin @ 52wk*3 mg
NCT02607865 · Phase 3 · converted to % from 137 Participants as posted
38.4% (n=466) vs 31.7% (n=467) Sitagliptin @ 78wk*3 mg
NCT02607865 · Phase 3 · converted to % from 179 Participants as posted
4.9% (n=184) vs 6% (n=184) placebo @ 26wk*3 mg
NCT03021187 · Phase 3 · converted to % from 9 Participants as posted
33.2% (n=184) vs 40.8% (n=184) placebo @ 52wk*3 mg
NCT03021187 · Phase 3 · converted to % from 61 Participants as posted
6.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
16.3% (n=49) vs 30.6% (n=49) placebo @ 52wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
0.8% (n=131) vs 1.5% (n=65) Dulaglutide @ 26wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
18.3% (n=131) vs 12.3% (n=65) Dulaglutide @ 52wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
8.7% (n=253) vs 18.7% (n=251) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 22 Participants as posted
15% (n=100) vs 26.5% (n=98) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted

+ 114 further endpoints in the CSV export.

Atherosclerotic Cardiovascular Disease

Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline

dulaglutide · Trulicity

Marketed by Eli Lilly

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT01394952 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).

Next expected readout: December 2030 · NCT07282041 (registry estimate)

Reported efficacy

Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 (met)

Result source: NCT01394952

Semaglutide (Rybelsus)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2029 · NCT07254572 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdulaglutideSemaglutide (Rybelsus)
LDL-C, % change—Trial running · NCT07282041—Not reported
Non-HDL-C, % change—Trial running · NCT07282041—Not reported
ApoB, % change—Trial running · NCT07282041—Not reported
Lp(a), % change—Trial running · NCT07282041—Not reported
3-point MACE (% with event)—Trial running · NCT07282041—Not reported

LDL-C, % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Rybelsus)
—Not reported

Non-HDL-C, % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Rybelsus)
—Not reported

ApoB, % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Rybelsus)
—Not reported

Lp(a), % change

dulaglutide
—Trial running · NCT07282041
Semaglutide (Rybelsus)
—Not reported

3-point MACE (% with event)

dulaglutide
—Trial running · NCT07282041
Semaglutide (Rybelsus)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Semaglutide (Rybelsus): no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

dulaglutide
Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 NCT01394952 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · Semaglutide (Rybelsus)'s landscape